Immunoprecise Stock Price, News & Analysis

ImmunoPrecise Antibodies (NASDAQ: IPA) has announced the sale of its Netherlands subsidiary, IPA Europe, to AVS Bio for $12 million USD, generating net proceeds of $11.7 million USD on a cash-free, debt-free basis.

The strategic divestment allows IPA to streamline operations and focus resources on its AI-based Software as a Service (SaaS) platform, LENSai™, powered by HYFT® multi-omics technology. The transaction includes a 12-month Transition Services Agreement to ensure operational continuity.

The proceeds will be used to invest in scientific platforms, data-driven discovery technologies, and expansion of key strategic programs, reinforcing IPA's commitment to accelerating biologics discovery through AI innovation.

AVS Bio, a portfolio company of Arlington Capital Partners, has acquired ImmunoPrecise Antibodies Europe (IPA Europe) from ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA). The acquisition strengthens AVS Bio's European presence and expands its capabilities in antibody discovery, protein expression, and organoid growth factor development.

IPA Europe, with facilities in Utrecht and Oss, Netherlands, provides comprehensive antibody discovery and characterization services, featuring advanced hybridoma and B-cell screening platforms. The company will maintain its existing management structure while operating as a strategic European hub within AVS Bio's network, serving pharmaceutical customers in both human and animal health markets.

ImmunoPrecise Antibodies (NASDAQ: IPA), a bio-native AI company, reported its fiscal year 2025 results with notable achievements. The company delivered record Q4 revenue of $7.0M and its best-ever quarterly Adjusted EBITDA of ($0.3M). Full-year revenue reached $24.5M, with gross margin expanding to 55% from 49% year-over-year.

The company's BioStrand segment grew over 180% in FY2025, now representing over 5% of total revenue with margins approaching 90%. IPA secured a strategic USD $8-10M partnership for antibody-drug conjugates development and demonstrated successful results with its LENSai platform, including breakthrough findings in dengue virus research and GLP-1 peptides development.

The company is strategically realigning to focus on AI-based product development and plans to complete the divestiture of its Dutch subsidiary to streamline operations.

ImmunoPrecise Antibodies (NASDAQ: IPA) has announced expanded study results for its LENSai™ Immunogenicity Screening technology, demonstrating its ability to predict Anti-Drug-Antibody (ADA) risk in therapeutic proteins before clinical trials. The study analyzed 217 marketed and clinical-stage antibodies, achieving a powerful discriminative capability with AUC=0.92.

The technology addresses a critical industry challenge, as up to 40% of biologics fail in late development due to ADA-related issues, resulting in potential losses of $1-2 billion per biologic. LENSai's HYFT-powered screening can evaluate nearly 900 HLA variants in one overnight run, offering significant time and cost advantages over traditional methods.

ImmunoPrecise Antibodies (NASDAQ: IPA), a bio-native AI company, has appointed Jeff Fried to its Advisory Board. Fried, currently Director of Platform Strategy and Innovations at InterSystems, brings over 25 years of experience in healthcare data infrastructure and AI innovation.

Fried has been a strong advocate for IPA's LENSai™ platform, which unifies biological sequence, structure, function, and scientific literature into a searchable, AI-ready framework. He has supported BioStrand's partnership with InterSystems to integrate advanced vector search capabilities into LENSai, enhancing AI-driven research capabilities.

ImmunoPrecise Antibodies (NASDAQ: IPA), a bio-native AI company focused on TechBio and next-generation drug discovery, has scheduled its Q4 and full fiscal year 2025 earnings conference call for July 29, 2025, at 10:30 AM ET.

The company will release its financial results before the call and host a live webcast with a Q&A session. Participants can join via phone using toll-free number (800) 715-9871 or international number +1 (646) 307-1963 with Conference ID 3224490, or through the webcast link available on IPA's investor relations website.

ImmunoPrecise Antibodies (NASDAQ: IPA) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or higher for 10 consecutive business days from June 26 through July 10, 2025, ensuring its continued listing on the Nasdaq Capital Market.

CEO Dr. Jennifer Bath highlighted this achievement as recognition of IPA's evolution into a platform company focused on bio-native AI. The company's proprietary LENSai™ platform, powered by HYFT® technology, is transforming therapeutic discovery by integrating various biological data types and enabling rapid, precision-guided development. The platform has demonstrated success in predicting therapeutic interactions for novel targets, achieving near-crystallography precision without prior training data.

ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-powered biotherapeutics company, has appointed Jon Lieber to its Board of Directors. Lieber, currently CFO at Rallybio, brings over 30 years of financial and strategic leadership in biotechnology and life sciences.

Lieber's expertise spans capital markets, investor relations, and corporate development. His experience includes CFO roles at companies like Applied Genetic Technologies Corporation (AGTC) and senior positions at Danforth Advisors, Histogenics, and Repligen. He currently serves on the Board of Directors of Salarius Pharmaceuticals and will contribute to IPA's commercialization and strategic growth initiatives, particularly in expanding their LENSai™ and HYFT® platforms.

ImmunoPrecise Antibodies (NASDAQ: IPA) has validated its AI-powered epitope mapping platform, LENSai, demonstrating its ability to accurately predict antibody binding sites on completely new, unseen therapeutic targets. The platform successfully mapped 17 previously unseen antibody-protein complexes with accuracy levels comparable to its performance on training data.

Powered by IPA's patented HYFT® technology, LENSai can predict binding sites in hours using only digital sequences, significantly reducing the time and cost compared to traditional lab-based methods that take months. The platform achieved consistent AUC (Area Under the Curve) scores across both familiar and new molecular complexes, proving its ability to generalize across diverse biological structures.